// App-Quantinova.ai

730P : Interim health related quality of life (QoL) from LAPACT, a Phase 2 trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC)

Researchers

Presenter

  • F.Portales

Principal Investigators

  • P.A.Philip

  • P.Hammel

  • M.Buscaglia

  • R.Pazo-Cid

  • J.L.Manzano Mozo

  • E.S.Kim

  • S.Dowden

  • A.Zakari

  • C.Borg

  • E.Terrebonne

  • F.Rivera Herrero

  • J.Shiansong Li

  • T.J.Ong

  • T.Nydam

  • J.Lacy

Medical Centers

  • Institut du Cancer de Montpellier, Montpellier, France

  • Department of Oncology, Karmanos Cancer Center, Detroit, MI

  • Gastroenterology, CHU Beaujon, Clichy, France

  • Medical Oncology, Azienda Ospedaliera Universitaria Senese, Siena, Italy

  • Medical Oncology, Hospital Universitario Miguel Servet, Zaragoza, Spain

  • Dermatology Service, Hospital Universitari Germans Trias i Pujol, Badalona, Spain

  • Medical Oncology, Levine Cancer Institute, Charlotte, NC, USA

  • Medical Oncology, Tom Baker Cancer Center, Calgary, AB, Canada

  • Gastro Intestinal Cancer Program, Florida Hospital Cancer Institute, Orlando, FL, USA

  • Centre Hospitalier de Montelimar, Montelimar, France

  • Medical Oncology, Hospital Haut Leveque, Giround, France

  • Hematology, Hospital Universitario Marques de Valdecilla, Santander, Spain

  • Biostatistics, Celgene Corporation, Summit, NJ, USA

  • Medical Affairs, Celgene Corporation - USA, Summit, NJ, USA

  • Medical Oncology Yale Cancer Center, New Haven, CT.

Locations

  • France

  • United States

  • Italy

  • Spain

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Gemcitabine

  • Paclitaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved